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Oncolytic virus therapy is based on the ability of viruses to eﬀectively infect and kill tumor cells without destroying the normal
tissues. While some viruses seem to have a natural preference for tumor cells, most viruses require the modiﬁcation of their
tropismtospeciﬁcallyenterandreplicateinsuchcells.Thisreviewaimstodescribethetransductionaltargetingstrategiescurrently
employedtospeciﬁcallyredirectvirusestowardssurfacereceptorsontumorcells.Threemajorstrategiescanbedistinguished;they
involve (i) the incorporation of new targeting speciﬁcity into a viral surface protein, (ii) the incorporation of a scaﬀold into a viral
surface protein to allow the attachment of targeting moieties, and (iii) the use of bispeciﬁc adapters to mediate targeting of a virus
to a speciﬁed moiety on a tumor cell. Of each strategy key features, advantages and limitations are discussed and examples are
given. Because of their potential to cause sustained, multiround infection—a desirable characteristic for eradicating tumors—
particular attention is given to viruses engineered to become self-targeted by the genomic expression of a bispeciﬁc adapter
protein.
1.Introduction
Cancer is one of the major health problems of our times.
Though the prognosis for people diagnosed with, at least
some forms of, cancer has increased considerably, it is more
typical a disease of which treatment is initially eﬀective, to be
followed later by an irreversible and eventually fatal relapse.
Already for decades, cancer treatment is based on three types
of approaches: surgery, radio-, and chemotherapy. While the
scientiﬁcandtechnologicaladvancementshaveimprovedthe
eﬃcacy of each of these classical approaches tremendously,
and while also some new therapies have evolved including
immunotherapy, the treatments apparently fail to eradicate
a l lr e s i d u a lt u m o rc e l l so rm e t a s t a s e sc o m p l e t e l y .T h e r e -
fore, additional means are urgently required to support or
replace the conventional therapies. Hence, a variety of new
approachesis currently being explored, one ofwhich is based
on the use of viruses.
Oncolytic viruses are deﬁned by their ability to specif-
ically kill tumor cells, but to leave the normal tissues un-
harmed. Their most characteristic features, thus, are their
target speciﬁcity and their cytolytic capacity. Ideally, they
exhibit additional features including, but not limited to,
a high reproductive capacity in vivo, the ability to recruit
uninfectedneighboringcells(syncytiaformation),theability
to infect both dividing and nondividing cells, a high stability
in vivo, the inability of chromosomal integration, the lack
of disease induction, and the general absence of preexisting
antibodies to the virus in the host population.
Infection of cells by viruses primarily depends on their
successful entry of these cells. As a ﬁrst step, virus-binding
to the cell relies on the speciﬁc interaction between the
viral attachment protein(s) and the cellular receptor(s). Only
very few viruses have a natural preference for replication in
tumor cells. Some acquired such tropism by serial passage
in cell culture cells; examples include measles virus, mumps
virus and Newcastle disease virus (recently reviewed in [1]),
vesicular stomatitis virus [2], and reovirus [3]. Many viruses,
however, lack the means for selective binding to tumor cell
epitopes. To adapt these viruses for oncolytic therapy, their2 Advances in Virology
natural tropism needs to be altered to allow binding to
tumor-speciﬁc receptors, an approach called transductional
targeting.
This review outlines the recent developments in trans-
ductional targeting of viruses. It will focus on the three
strategiesforretargetingofvirusesthatseemmostpromising
for the development of new oncolytic viruses. Section 2
will review the strategy through which viruses could be
successfully provided new tropism by introducing targeting
information into one of the viral surface proteins. As this
strategy has been investigated most actively, we will limit
the overview of the examples to those viruses in which
the new targeting speciﬁcity could be genomically encoded.
In Section 3, approaches are described by which scaﬀold-
based modiﬁcations of viral surface proteins were applied
to direct virions to new target cells, including the use of
biotin or antibody-binding moieties. Section 4 will review
the use of bispeciﬁc adapter proteins as mediators of binding
virions to tumor cells. Most often such adapters were simply
combined with the respective viruses thereby enabling
single-round infection. In some cases, these targeting devices
were incorporated genetically into the virus so as to generate
self-targeted agents able to independently spread through a
tumor. Finally, the review will be completed with general
conclusions on the current status of the ﬁeld of oncolytic
virotherapy and with views on its future.
2.Modiﬁcation of ViralSurfaceProteins
The most popular approach to generate oncolytic viruses has
been by adapting their surface-exposed components. Viral
surface proteins can be modiﬁed to express ligands that
bind to receptors preferentially or exclusively expressed on
tumor cells. Viruses can be genetically adapted to express
those modiﬁcations to redirect them towards tumor cells
(Figures 1(a) and 1(b)). The main advantage of this strategy
is that the targeting speciﬁcity is inherent to the viral genome
and will, thus, be maintained upon replication. Progeny
virus is then able to infect neighboring cells harboring the
target receptor, thereby establishing a multiround infection
that will be maintained until no further tumor target cells
remain. For this strategy, the ability to genetically modify
the viral genome is crucial. Furthermore, detailed structural
information about the viral surface protein to be modiﬁed
is indispensible to predict at which location targeting motifs
m i g h tb et o l e r a t e da n dw i l lb ee x p o s e d .S u c hm o t i f ss h o u l d
not only allow binding of the modiﬁed virion to the cells
but should also not be detrimental to the entry mechanism
of the particular virus, not interfering for instance with
the fusion of viral and cellular membrane. In addition, the
targeting ligand introduced into the viral protein will have
to meet size limitations. Small peptides, thus, seem the ﬁrst
and most obvious choice. The development of targeting
strategiesofvirusesis,however,severelylimitedbyashortage
of naturally existing molecules available for use as targeting
ligands. Therefore, other sources of binding ligands have
been investigated and incorporated into viral proteins for
this purpose. These include (parts of) antibodies, like scFvs
(single-chain variable fragments, composed of a fusion of
the variable regions of the heavy (VH) and light chains (VL)
of an immunoglobulin) or Fabs (antigen-binding fragments,
composed of one constant and one variable domain from
each heavy and light chain of the antibody). The feasibility
of modifying viral coat proteins has been demonstrated for a
number of viruses as is summarized below.
2.1. Adenoviruses. Adenoviruses are among the most exten-
sively studied viruses for oncolytic viral therapy. In a wild-
typeinfection,adenovirus-bindingtothecellsismediatedby
its major attachment factor, the ﬁber protein. Via its carboxy
terminal knob domain, this protein binds to the primary
cellular receptor coxsackie/adenovirus receptor (CAR). Fol-
lowing viral attachment, internalization is mediated through
interaction of RGD motifs in the penton base with cellular αν
integrins. In order to achieve CAR-independent infection by
adenoviruses, the viral tropism can be modiﬁed via genetic
engineering of adenovirus capsid proteins.
The list of reviews describing the development of gene-
tically redirected adenoviruses through incorporation of
ligands into viral surface proteins is numerous. In summary,
heterologous peptide ligands have been successfully engi-
neered into many adenoviral proteins, including the HI loop
of the ﬁber, the C terminus of the ﬁber, the L1 loop in the
hexon, and the RGD loop in the penton base and in the
minor capsid protein IX. Most commonly, targeting moieties
are inserted in the HI loop of the ﬁber knob. For this protein,
theimportanceoftheinsertionsiteoftheligandwasdemon-
strated when introducing a model peptide CDCRGDCFC
into the knob [4]. The insertion of the ligand into three of
ﬁve analyzed loops of the knob still allowed trimerization
of the knob protein, and the resulting adenoviruses showed
superior infectivity to that of viruses with the same peptide
fused to the ﬁber C terminus. That the precise ligand
positioning is pivotal was further demonstrated by the lack
of enhancement of infectivity when the ligand-ﬂanking
linkers were extended and when tandem copies of the ligand
peptide were inserted [5]. Interestingly, also antibody-based
targeting could be achieved for adenoviruses by generating
ﬁber chimeras [6] or fusions of scFvs with the capsid protein
IX [7]. For the most recent reviews on transductionally
targeted adenoviruses, the reader is referred to [8–11]. For
adenoviruses, the possibility to combine transductional with
transcriptional targeting to increase adenoviral speciﬁcity
makes this group of viruses particularly interesting for future
therapy; however, their strong immunogenic nature might
seriously hamper their eﬃcacy in vivo.
2.2. Paramyxoviruses-Measles Virus. The measles virus is
another virus well studied for oncolytic therapy, as the
attenuated measles virus strain Edmonston has the ability
to selectively destroy neoplastic tissue (reviewed in [12]).
Measles virus has two envelope glycoproteins: the hemag-
glutinin (H) attachment protein and the fusion (F) protein.
Virus attachment, entry, and subsequent cell-cell fusion are
mediated via the two measles receptors: CD46 and the
signaling lymphocyte activation molecule (SLAM).Advances in Virology 3
Virus
Tumor cell
(a)
(b)
(c)
Fab
Antibody
scFv
Ig-binding
domain
VL
VL
VL
VL
VH
VH
VH
VH
Peptide/vitamin ligand
CL
CL
CL
CH
CH
CH
Avidin-polymer-
peptide
Chemical “click”
Peptide/vitamin
ligand
Avidin
Biotin
Biotin peptide
Figure 1: Transductional targeting through the modiﬁcation of viral surface proteins. (a) Principle of redirecting viruses by the insertion
of tumor-speciﬁc ligands into the viral coat, without modiﬁcation of viral surface protein (upper part) no infection; (b) Schematic
representation of a viral surface protein (represented by the grey-ﬁlled circle) on which tumor-binding peptides or antibodies are exposed.
Ligands can be introduced at the N- or C-terminus of the protein or internally, provided that the correct folding of the viral protein and
its accessibility for binding to the cell surface receptor are maintained; (c) Schematic representation of a viral surface protein on which a
scaﬀold is exposed. The targeting ligand, examples of which are shown schematically, is then provided as a separate entity, binding on the
one hand to the virion and on the other hand to the cell surface receptor of choice.
Toimprovethespeciﬁcityoftheinfection,tumor-speciﬁc
ligands have been introduced as C-terminal extensions of the
H protein. A range of ligands, including both peptides and
scFvs,weretoleratedand,inaddition,allowedtheredirection
of the virus to cells expressing the appropriate virus receptor.
Again, the nature of the ligands was pivotal. Thus, though
the length of the linkers separating the VH and VL domains
was not of importance for scFvs to be incorporated into
virions, it certainly aﬀected the membrane fusion ability of
thevirus[13].Forreviewsonredirectedmeaslesvirus,please
see [12, 14–16]. As the Edmonston strain has been used
for vaccination for over 50 years now, its safety proﬁle is
impressive and might provide a good basis for future appli-
cation in oncolytic therapy.4 Advances in Virology
2.3. Herpesviruses-Herpes Simplex Virus (HSV). Another
ﬁeld of active study involves the use of herpes simplex virus
for tumor therapy (reviewed in [17, 18]). Herpesvirus in-
fects cells by attachment to heparan sulfate proteoglycans,
mediated by the viral glycoproteins gC and gB, followed
by the interaction of the glycoprotein gD with one of two
alternative protein receptors. One, designated herpesvirus
entry mediator, is a member of the family of tumor necrosis
factors receptors. The second involves nectin1 and nectin2,
both intercellular adhesion molecules belonging to the
immunoglobulin (Ig) superfamily.
Retargeting of HSV could be achieved by the insertion of
ligands and scFvs into the gC and/or the gD protein, with
subsequent increased infectivity of target cells expressing the
appropriate virus receptor. The current strategies to redirect
HSV towards tumor cells have recently been reviewed [18,
19].Foranotherherpesvirus,thegammaherpesvirussaimiri
the native binding region of the viral glycoprotein ORF51
to heparan sulphate was replaced with that of a peptide
sequence interacting with somatostatin receptors, known
to be overexpressed on hepatocellular carcinoma cells. The
subsequent recombinant virus appeared to infect the car-
cinoma cells as well as the wild-type virus, while showing
reduced infectivity for other cell lines. The reason for these
observations is unclear [20]. In conclusion, herpesviruses
remain promising as candidates for oncolytic therapy as
they can be redirected to tumor cells and are considered
reasonably safe due to the induction of a self-limited disease
in humans. On the other hand, their wide natural tropism
andthepresenceofviralantibodiesinthehumanpopulation
might hamper their eﬀectiveness in vivo.
2.4. Parvoviruses-Adenoassociated Virus (AAV). Al e s sf r e -
quentlystudiedcandidatefordevelopmentasoncolyticagent
is AAV (reviewed in [21]). AAV has a broad host cell range
due to the widespread distribution of its primary cellular
receptor heparan sulfate proteoglycan. The viral capsid pro-
tein is responsible for the interaction with this host cell
receptor.
Transductional targeting independent of the native
tropism could be demonstrated by genetically incorporating
the 14-amino-acid targeting peptide L14 [22] into six diﬀer-
ent putative loops of the AAV2 capsid protein. The results
showed that all mutant capsids were eﬃciently incorporated,
that three mutants expressed L14 on the capsid surface,
but that only one of these eﬃciently infected wild-type
AAV2-resistant cell lines that expressed the integrin receptor
recognized by L14. The importance of the incorporation
site and of the peptide sequence was further elucidated in
other studies, showing that the assembly, the generation
of infectious particles, and the ability to transduce target
cells depends both on the position in the capsid and on
the ligand introduced [23, 24]. Successful targeting was
demonstrated towards RGD [25] and towards the human
luteinizing hormone receptor [24]. Due to the broad cell
tropism of wild-type AAV, retargeting in combination with
ablation of its natural tropism will remain crucial to develop
this virus into a safe oncolytic vector.
2.5. Retroviruses-Murine Leukemia Virus (MuLV). Replica-
tion-competentretroviruseshavegainedinterestasoncolytic
agents, in particular because of their high transduction
eﬃciency (reviewed in [26, 27]). Of MuLV diﬀerent classes
can be distinguished, of which the host range is based on
the interaction between the envelope glycoprotein and a
particular cell surface receptor. While the ecotropic MuLVs
are particularly capable of infecting mouse and rat cells,
amphotropic MuLV infects a range of mammalian, including
human cells via the widely expressed Pit-2 receptor.
InitialstudiestoredirectecotropicMuLVtowardshuman
tumor cells pointed towards the importance of the inter-
action between the envelope glycoprotein and its original
virus receptor. Despite the correct folding of chimeric
envelope glycoproteins displaying scFvs, their incorporation
into viral particles, and the binding of pseudotyped virus
particles carrying chimeric ecotropic Env to human cells,
the resulting viruses were not infectious for the targeted
cells (reviewed in [28]). When expanding these studies
using amphotropic MuLV, targeted infection could be
achieved only when incorporating the high molecular weight
melanoma-associated antigen (HMWMAA), while targeting
towardstheEGF[29],IGF[30],andfolate[31]r ec ept orswas
unsuccessful, despite the observed binding to cells expressing
those receptors. It was proposed that traﬃcking of the
virus particles to lysosomes and subsequent degradation
caused the lack of infectivity, but attempts to overcome this
problembyinsertingatranslocationdomainofexotoxinAof
Pseudomonas aeruginosa into the envelope protein, in order
to translocate the virion from endosomes to the cytoplasm,
were unsuccessful [29]. Clearly, the choice of receptor will
be of ultimate importance for the successful targeting of
retrovirus vectors towards tumor cells.
2.6. Poxviruses-Vaccinia Virus. Vaccinia virus has been stud-
ied for its antitumor properties already for a long time.
Despiteitsentryintoawiderangeofcells,forseveralvaccinia
virus strains, a natural preference for replication in cancer
tissue has been reported. While the identity of the natural
receptor is still under debate, it likely involves a widely ex-
pressedsurfacecomponent,likeheparansulfateorchondroi-
tin sulfate proteoglycans. Tumor targeting can be improved
by deleting vaccinia virus genes that are necessary for re-
plication in normal cells but not in cancer cells (recently
reviewed in [32]).
To increase the speciﬁcity of their tropism, tumor-
speciﬁc scFvs have been displayed on the surface of vaccinia
virus particles. Targeting moieties were introduced by fusing
an scFv directed against the tumor-associated antigen ErbB2
to the N-terminus of the nonessential hemagglutinin HA
protein in vaccinia virus strain IHD-J [33]. Similarly, the
nonessential p14 membrane-associated protein of vaccinia
strainMVAcouldbereplacedwithap14fusionmoleculecar-
rying an inserted scFv directed against the tumor-associated
antigen MUC-1 [34]. The resulting fusion proteins could be
expressed, were exposed on the envelope of the recombinant
virus, and were able to bind the target cells. No preferential
infection of the target cells was, however, observed, likelyAdvances in Virology 5
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Figure 2: Modiﬁcation of viral surface proteins for redirecting coronavirus to tumor cells. Schematic representation of MHV surface
glycoproteins spike (S) and hemagglutinin-esterase (HE) and of modiﬁcations applied to redirect the virus to novel target cell antigens.
Modiﬁcations tested include: insertion of small peptide ligands, including RGD and NGR, and extension with the anti-EGFR scFv425.
Recombinant MHV viruses encoding such mutated S proteins or modiﬁed HE proteins (in the presence of wild type spike proteins) were
generated by targeted recombination [35]. Indicated is whether the intended recombinant viruses could actually be isolated (conﬁrmed by
RT-PCR and sequencing). Also indicated is the tropism of each successfully generated recombinant virus for murine and for human cells
(Verheije and Rottier, unpublished data).
because the recombinant viruses still contained wild-type
host cell attachment proteins, providing the infection with
a broad cell range. Therefore, the future challenge for the
transductionaltargetingofvacciniavirustowardstumorcells
will lie in the elimination of its natural tropism.
2.7.Coronaviruses-MouseHepatitisVirus(MHV). Thefavor-
able characteristics of—particularly the nonhuman—coron-
aviruses as potential oncolytic agents have been recognized
only recently. In these viruses, the spike (S) protein is
responsible for receptor binding and subsequent cell entry
through virus-cell membrane fusion. The aminoterminal
S1 domain is required for virus-binding to the cells, and,
while undergoing ordered structural changes, the S2 domain
mediates fusion with the cell membrane. Infection of cells by
coronaviruses depends on the expression of speciﬁc cellular
receptors, which makes these viruses highly species-speciﬁc.
For example, entry by MHV is mediated by the murine
carcinoembryonic antigen (CEACAM1a) receptor.
Attempts to redirect coronaviruses, in particular MHV,
by mutation of the viral surface proteins were unsuccessful.
Incorporation of ligands, such as RGD and NGR, into
various nonconserved domains in the S1 domain of the spike
protein appeared to be not tolerated, as the selection of
retargeted recombinant viruses based on the new binding
properties of the modiﬁed spike was not successful (Figure 2;
Verheije and Rottier, unpublished data). Obviously, without
much knowledge of the tertiary structure of the coronavirus
spike protein and of its conformational changes during cell
entry, chances are high that the introduction of even small
ligands aﬀects its proper functioning. Some MHV strains
carry an accessory hemagglutinin-esterase (HE) surface
glycoprotein. Attempts to also use this glycoprotein for
retargetingwereequallyunsuccessful.ThoughsomeHEgene
modiﬁcations,suchasinsertionsofsmallpeptideligandsand
terminal extensions with the anti-EGFR scFv425, could be
incorporated into the viral genome, the resulting recombi-
nant viruses were unable to redirect MHV to human tumor
cells (Figure 2; Verheije and Rottier, unpublished data).
3. Introduction of Scaffolds into
ViralSurfaceProteins
Rather than incorporating speciﬁc tumor targeting infor-
mation into a viral surface protein, an alternative approach
involves the incorporation of a scaﬀold moiety into such
a protein to which subsequently various types of tar-
geting modules can be linked (schematically depicted in
Figure 1(c)). The main strategic diﬀerence relative to the
previous method is that the moiety incorporated is not a
tumor ligand itself but represents an attachment site for
exogenously provided targeting moieties that, besides to6 Advances in Virology
the scaﬀold, also bind to the receptor of interest (compare
Figures 1(b) and 1(c)). An essential operational limitation
is that this targeting strategy provides viruses that can only
establish single-round infection, remaining dependent on
the external supply of the targeting module. Yet, it has
the advantage of ﬂexibility as the targeting device, binding
always to the same, previously modiﬁed viral protein, can
be changed relatively easy. Some of these strategies are based
on antibody targeting, giving the opportunity to redirect the
oncolytic virus to virtually every tumor surface epitope. A
particular application based on this principle relies on the
biotin-(strept)avidin-coupling method (reviewed in [36]).
3.1. Adenoviruses. For adenoviruses, single-round targeted
virus particles could be generated by using the biotin-
streptavidin coupling system. After incorporating a bioti-
nacceptor peptide into the ﬁber, metabolically biotinylated
adenovirus was coupled to an EGF-streptavidin complex
and found to successfully infect EGFR expressing target
cells [37]. Similarly, a biotin-polyethylene glycol (PEG)-EGF
conjugate coupled to an avidin-modiﬁed adenovirus could
redirect the virus to a nonnative receptor [38]. In another
study, small protein ligands capable of selective binding to
human IgG and IgA were incorporated as model ligands
for tropism-modiﬁed adenoviruses. Viable viruses that had
genetically incorporated scaﬀolds into their ﬁber gene could
be rescued and were, after incubation with antibodies,
able to enter cells displaying the Fc receptor on their
surface [39]. Recently, it has been demonstrated that speciﬁc
chemoselective modiﬁcation of the adenoviral particle could
also function as a scaﬀold for targeting devices. By metabolic
incorporation of noncanonical monosaccharides and amino
acids in adenoviral particles, conjugation with a folate
targeting motif in combination with a taxoid was achieved.
Initial results demonstrated increased toxicity in vitro [40].
3.2. Adenoassociated Virus. The Ig-binding fragment of
p r o t e i nAw a st e s t e da sap o s s i b l es c a ﬀold to redirect AAV.
The fragment was successfully introduced into the capsid
protein providing a versatile platform forantibody-mediated
AAV targeting [41] .I nam o r er e c e n ts t u d y ,ab i o t i n a c c e p t o r
peptide was incorporated into AAV particles. Subsequent
biotin labeling of the viruses with the biotin ligase BirA and
attachment of an RGD peptide to target integrins resulted in
a signiﬁcant increase in the transduction of endothelial cells,
demonstrating again the feasibility of this approach [42].
3.3. Togaviruses-Sindbis Virus. Sindbis virus has inherent
oncolytic properties and has been studied quite extensively
as an oncolytic virus (reviewed in [43]). One of the surface
proteins on mammalian cells to mediate the Sindbis virus
infection is the laminin receptor, which is overexpressed on
various human tumors. The envelope protein E2 of Sindbis
virus is responsible for receptor binding.
To increase the speciﬁcity of the infection, researchers
combined the introduction of ligands into the viral envelope
with the use of targeting molecules. To this end, virus
particles were generated which contained the IgG-binding
domain of protein A inserted into their envelope protein
E2. When combined with antibodies that bound to speciﬁc
surface antigens on nonsusceptible cells, the chimeric virus
was able to infect these otherwise refractory cells [44]. A
comparablecombinationapproachwastakenbyintroducing
Ig-binding domains as N-terminal extensions of the E2
glycoprotein. After adding species-matched antibodies, Fc
receptor-positive cell lines could be successfully infected
[45].
3.4. Murine Leukemia Virus. Also for MLV, studies were
performed to introduce the IgG-binding domain of protein
A to enable modular use of antibodies of various speciﬁcities
for vector targeting. By inserting this binding domain into
the hinge region of the viral envelope protein virions were
generated that were capable of capturing anti-HER2 anti-
bodies. Subsequent eﬃcient binding of the virus-antibody
complex to HER2-positive target cells and enhancement of
transduction of these cells was observed [46].
4.TransductionalTargeting of Viruses
UsingBispeciﬁcAdapters
4.1. Bispeciﬁc Adapters. An elegant strategy currently
employed to target viruses towards tumor cells makes
use of bispeciﬁc adapters. Such proteins consist of two
domains (“arms”), one binding to the virion, the other to
a cell surface epitope of interest, thereby enabling indirect
interaction of virus and tumor cell. The composition of
the adapter proteins can vary greatly, depending on the
design of the arms. The virus-binding domains that have
been used include soluble receptor fragments (so-called
pseudoreceptors), polymers like PEG, (parts of) antibodies,
including scFvs or Fabs. Moieties that have been applied
for cell-binding are natural peptide or vitamin ligands for
receptors, and again scFvs or Fabs directed against a cell
epitope of interest. The speciﬁcity for two diﬀerent antigens
is achieved either by joining the arms together chemically
or by combining the two moieties in one fusion protein,
often with a ﬂexible linker, the targeting arm typically
being at the C-terminus. The principle of redirecting viruses
towards nonnative cells using bispeciﬁc proteins is shown in
Figure 3(a), with typical examples of the two domains being
depictedinFigure 3(b).InTable 1,anoverviewisprovidedof
combinations of arms in bispeciﬁc adapter proteins actually
generated to target viruses to tumor cells.
4.2. Advantages and Disadvantages of Bispeciﬁc Adapters for
Targeting. The use of adapters to redirect viruses towards
tumor cells has several advantages over the introduction of
targeting or scaﬀold moieties into viral attachment proteins.
First,nodetailedstructuralinformationisrequiredaboutthe
viral surface proteins, as the manipulation of these proteins
is not required. Second, as the size of the targeting part of
the adapter protein seems less crucial than when introducing
this moiety into a viral protein, the choice of targets can
easily be expanded by using (parts of) antibodies. In this
way, the selection of targeting receptors becomes virtuallyAdvances in Virology 7
CL
CH
CL
CH
VL
VL
VH
VH
VL
VH
VL
VH
Peptide
Virus Bispeciﬁc protein Cell
scFv
scFv
Polymer
(a)
(b) Virus-binding arms Cell-binding arms
Fab
Fab
Pseudoreceptor
Figure 3: Bispeciﬁc adapter targeting principle and composition. (a) Principle of targeting viruses towards tumor cells using bispeciﬁc
adapters. (b) Typical examples of virus-binding moieties (left) and cell-binding moieties (right) of bispeciﬁc adapters. In theory, all
combinations of virus-binding and cell-binding arms are possible. An overview of the composition of the bispeciﬁc adapters used to target
particular viruses to tumor cells is provided in Table 1.
Table 1: Overview of the composition of bispeciﬁc adapters used to reroute viruses for oncolytic purposes.
Adaptor protein moiety binding to Targeting demonstrated for
Virion Cell
Antibody (scFv or Fab) Antibody (scFv or Fab)
Adenovirus
Adenoassociated virus
Coronavirus
Antibody (scFv or Fab) Ligand peptide Adenovirus
Paramyxovirus
Soluble/pseudo receptor Antibody (scFv or Fab)
Adenovirus
Herpesvirus
Coronavirus
Soluble/pseudo receptor Ligand peptide Adenovirus
Coronavirus
Polymer Antibody (scFv or Fab) Adenovirus
Polymer Ligand peptide Adenovirus
unlimited, as antibodies can be generated relatively easy,
once the receptor of interest has been identiﬁed. Third, as
adapter proteins are straightforward to construct, expanding
the repertoire of target receptors becomes relatively easy.
Finally, the binding of adapter proteins to the virion has, at
least in some cases, been reported to ablate the virus’ natural
tropism, which is especially useful when the oncolytic virus
of choice has a preference for normal cells in the host.
There are also disadvantages of using bispeciﬁc pro-
teins in targeting oncolytic viruses. As bispeciﬁc proteins
are artiﬁcial polypeptides composed of parts that do not
occur linked together naturally, their proper biogenesis with8 Advances in Virology
independent folding of both moieties and eﬃcient secre-
tion may be impaired. Moreover, unless expressed by the
oncolytic virus itself, production and puriﬁcation of the
adaptors is a challenge.
4.3. Application of Bispeciﬁc Adapters. To redirect oncolytic
viruses towards tumor cells, bispeciﬁc proteins can be
applied in two ways. First, after recombinant production or
chemical synthesis, the proteins can be precomplexed with
virions before applying them in vitro or in vivo.Am a j o r
drawback of this approach is, however, that it allows single-
round infection only; progeny virus will not be able to
infect neighboring cells as the amount of adapter protein
will be limiting. Consequently, the use of such adapter-
precomplexed viruses in vivo is likely to be restricted to
local, rather than systemic application. It will probably also
require repeated administration of high doses of the adapter
proteins. Little is known about the potential risks of such
approach.
As an alternative, the genetic information for the adapter
protein can be incorporated into the viral genome. When
properly expressed, this ensures the local production of
the targeting device together with the progeny virus in the
infected cell. This approach will enable multiround infection
and lateral spread of the oncolytic virus. The time span and,
hence, the eﬃcacy of this kind of therapy will be limited by
the emergence of immunity against the bispeciﬁc protein
and/or the virus. The feasibility of this strategy depends on
the availability of a genetic modiﬁcation system to introduce
the adapter-encoding gene into the viral genome as an
additional expression cassette. While such modiﬁcation
systems are currently available for most viruses, the capacity
of the genome to accept such insertions can be limited;
hence, the size of the targeting moiety might be restricted.
Finally, the genetic stability of such recombinant viruses
might be an issue, in particular when the adapter protein is
used to ablate the natural tropism of the virus.
The feasibility of using adapter proteins for oncolytic
viral therapy has been explored for a number of viruses.
Belowweﬁrstpresentanoverviewofthestudiesinwhichtar-
geting to tumor cells was performed by coadministration of
viruses and adaptor proteins (Section 4.3.1). Thereafter, we
discuss the studies describing genetic targeting of oncolytic
viruses generated by the incorporation of genes coding for
bispeciﬁc proteins into the viral genome (Section 4.3.2).
4.3.1. Single-Round Transductional Targeting
Using Bispeciﬁc Adapters
Adenoviruses. To redirect adenoviruses to tumor cells, neu-
tralizing antiknob ﬁber antibodies have been used exten-
sively. The ﬁrst demonstration of their potential application
for retargeting of these viruses to a nonadenovirus cellular
receptor was in 1996, when such antibodies were chemically
conjugated to folate and shown to mediate infection of
folate-receptor expressing cells [47]. Many nonnative recep-
tors have since been targeted by conjugating an antiknob
antibody fragment to either ligand peptides or antibody
domains directed against a cellular receptor. This resulted
in successful targeting towards the EGF receptor (EGFR)
[48, 49], FGF receptor [50–52], integrins [53, 54], EGP-2
(also known as EpCAM) [55, 56], the melanoma-associated
antigen HMWMAA receptor [57], carbonic anhydrase IX
protein G250 [58], CD40 [59, 60], various organ- and
tumor homing peptide receptors [61], mesothelin MSLN
[62], prostate-speciﬁc membrane antigen PSMA [54, 63],
VEGFR2 [54], Ly-6D [64], and Tie2 receptors [54].
Similar approaches have been explored using antibod-
ies directed against other adenoviral proteins. Thus, Fabs
directed against the penton base of the ﬁber in combina-
tion with targeting ligands, such as EGF, IGF, and TNFα
could mediate the infection of target cells expressing the
appropriate receptors [65]. Also Fabs directed against the
hexon protein chemically linked to Fabs speciﬁcally binding
to an antigen highly overexpressed on human hepatocellular
carcinoma were successfully applied to redirect adenoviruses
to a nonnative receptor [66].
Another strategy successfully employed for the same
purpose made use of pseudoreceptors. In this approach,
bispeciﬁcproteinsweregeneratedbyfusionofasolubleform
of CAR (sCAR) to EGF [67, 68], to the Fc region of human
IgG1 [69], and to scFvs against ErbB2 [70] and CEA [71].
In yet another approach, polymers were exploited as
targeting ligands in a single round fashion. Here, adenovirus
particles were coated to inhibit their natural tropism after
which ligands, including peptides and scFvs, were attached.
Several types of polymers have been used [72–77], including
polyethylene and metacrylamide derivatives, to successfully
target adenoviruses to FGF2 [78], RGD [79], TNFα [80], and
theHER2receptor[81].Ithasbeenproposedthatadenoviral
coating with polymers might have enhanced potential for
systemic delivery, as it prolongs the viral plasma half-live and
reduces the hepatotoxicity in vivo [80].
Finally, another type of bispeciﬁc molecule based on
the binding ability of the Gla domain of coagulation factor
X to the hexon was exploited for targeting. Upon fusion
of Gla to scFv proteins, increased infection of tumor cells
by adenovirus could be observed. However, the anticipated
reduction in liver transduction was not observed [82].
AdenoassociatedViruses. AAVhasabroadhostcellrangedue
tothewidespreaddistributionofitsprimarycellularreceptor
heparan sulfate proteoglycan. To achieve a more speciﬁc
infection, a bispeciﬁc Fab was tested of which one arm
recognized the cell-surface integrins αIIbβ3 while the other
bound to the AAV capsid [83]. Targeting this way did not
inhibit downstream steps required for productive infection.
Moreover,adecreaseofinfectionofnormallypermissivecells
was observed, indicating that the bispeciﬁc protein was able
to ablate the normal tropism.
Herpesviruses-Herpes Simplex Virus. HSV binding to the cell
is mediated by several widelyexpressed cellsurfacereceptors,
including nectin1. HSV was successfully redirected to the
EGFR by means of a soluble adapter protein comprising
the N-terminal domain of nectin1 fused to an scFv directedAdvances in Virology 9
against EGFR [84]. Adapter-mediated entry was, however,
promoted by the presence of heparan sulfate proteoglycans
oncells,whicharealsorequiredforwild-typeHSVinfection.
Paramyxoviruses-Newcastle Disease Virus (NDV). In the
avian paramyxovirus NDV, the hemagglutinin-neuramini-
dase (HN) protein is responsible for sialic acid receptor
attachment, while the F protein mediates the fusion of
viral envelope and cellular membrane. NDV has oncolytic
properties by nature; however, it has a broad cell tropism
due to the widespread occurrence of sialic acids on many
cells. To narrow its speciﬁcity, the use of bispeciﬁc adapter
proteins has been investigated. Preincubation of NDV with a
recombinant bispeciﬁc protein composed of an scFv against
HN that blocks the native receptor binding site and the
interleukin-2 peptide clearly enhanced the speciﬁcity of
the virus [85] and reduced its side-eﬀects when applied
systemically in vivo [86].
Coronaviruses-Mouse Hepatitis Coronavirus (MHV) and
Feline Infectious Peritonitis Virus (FIPV). The ﬁrst demon-
stration of retargeting of coronaviruses was achieved by
exchanging the viral spike ectodomains. Thus, felinized
MHV (fMHV) [87] and murinized FIPV (mFIPV) [35]
were generated in which the murine viruses carried the
feline S ectodomain and vice versa. These otherwise highly
species-speciﬁc recombinant viruses were able to cross
species barriers; fMHV had acquired feline cell tropism but
completelylostitsmurinecelltropismwhiletheoppositewas
true for mFIPV. To extend the species tropism of nonhuman
coronaviruses towards human tumor cells, bispeciﬁc adapter
proteins were generated. Proteins composed of a bispeciﬁc
scFv directed against both the feline spike protein and the
EGFR could mediate FIPV and fMHV infection of EGFR-
expressing human cancer cells, with subsequent syncytia
formation typical of a productive coronavirus infection [88].
Subsequent studies to redirect murine coronavirus MHV
to human tumor cells were based on an adapter protein
that consisted of a pseudoreceptor, composed of the N-
terminal domain of murine CEACAM1a (soluble receptor;
soR), fused to an scFv directed against the EGFR [89]o r
to the EGF ligand [90]. Again, such adapter proteins could
mediate EGFR-speciﬁc entry of MHV into human cancer
cells. However, in contrast to many of the previous examples,
no ablation of the natural tropism of the virus was observed.
4.3.2. Multiple-Round Transductional Targeting Using Bispe-
ciﬁc Adapters. To overcome the major drawback inherent to
single-round targeting, a number of investigations focused
on the expression of the bispeciﬁc adapters from the viral
genomeinordertoallowtherecombinantvirusestoproduce
their own targeting device and sustain the infection. The
feasibilityofthisapproachhassofaronlybeendemonstrated
for some adenoviruses and coronaviruses.
Adenoviruses. To redirect adenoviruses to nonnative surface
receptors, conditionally replicating adenoviruses (CRAds)
seem to be the viruses of choice, due to their selective
replication in tumor cells. The ﬁrst experiments demon-
strating the ability to redirect CRAds towards tumor cells
were performed using dual-virus mixtures consisting of
a CRAd and an adenovirus secreting a bispeciﬁc adapter
protein consisting of a fusion between the soluble CAR
receptor and the EGF ligand [91]. Dual virus infections
resulted in increased oncolytic activity in vitro and improved
therapeutic eﬃcacy in vivo.
Subsequently, CRAds were engineered to express the
bispeciﬁc adapter proteins by themselves. Van Beusechem
et al. [92] developed such a CRAd encoding a bispeciﬁc
protein composed of the anti-EGFR scFv 425 and antiﬁber
knob scFv s11. The resulting virus AdΔ24-425S11 produced
the bispeciﬁc protein 425-s11 during replication in cancer
cells, yielding progeny virus with enhanced infectivity and
oncolyticpropertiesonEGFR-positive,CAR-deﬁcienttumor
cells. However, in addition to infection mediated by EGFR,
the virus retained its capacity to infect cells through binding
to the native receptors CAR and integrins. To abolish the
native tropism, mutations were introduced that eliminated
CAR and integrin binding [93], resulting in a recombinant
virus with a strictly EGFR-dependent targeting proﬁle and
reduced replication in EGFR-negative cells. Both viruses
displayed similar oncolytic potency in cell lines and tissue
specimens [93]. Also when applied in a mouse model by
intrajugular or intramuscular injection, the native tropism
of adenoviruses appeared to be reduced after the removal
of both the CAR and integrin-binding sites [94]. Strikingly,
however, when expressing the soluble CAR-EGF targeting
moiety from a CRAd rather than from a dual virus system,
its oncolytic potential was severely impaired [95], suggesting
that the expression of biologically active proteins can be
counterproductive to virus replication.
To overcome the biosynthetic diﬀerences between the
bispeciﬁc proteins translated and secreted via the ER-
Golgi route and the adenovirus with translation in the
cytoplasm but assembly in the nucleus, an elegant strategy
was developed by tagging of the adenovirus ﬁber and the
scFv each with a synthetic leucine zipper-like dimerization
domain [96]. Tagging of the proteins with the zipper peptide
sequences preserved both the trimerization capability of the
adenovirus ﬁber and the recognition of the EGFR by the
zipper-scFv protein, but, most importantly, it gave rise to
receptor-speciﬁc infection of the target cells.
Several studies have shown the feasibility of using bispe-
ciﬁcproteinsforredirectingadenovirusestowardstargetcells
ex vivo or in vivo in laboratory animal models, including [71,
92, 97–102]. Although quite eﬀective, these studies were all
based on a two-component strategy, requiring the mixing of
virionswithbispeciﬁcproteinsbeforeadministration.Toour
knowledge, no in vivo studies have yet been performed using
recombinant adenoviruses expressing a bispeciﬁc adapter
from their viral genome to establish whether they have
superior targeting and cell-killing abilities.
Coronaviruses. To generate self-targeted coronaviruses, ini-
tially the coding sequence for a bispeciﬁc adapter protein
composed of the soluble mCEACAM1a receptor linked to10 Advances in Virology
a His-tag was incorporated into the MHV viral genome
by targeted recombination, creating the virus-designated
MHVsoR-His [103]. The presence of this additional expres-
sion cassette was tolerated and the resulting recombinant
viruses indeed expressed the adapter protein. Inoculation of
target cells expressing the artiﬁcial His-receptor on their sur-
face showed the recombinant viruses to be able to establish
a multiround, receptor-dependent infection. Furthermore,
extensive cell-cell fusion and rapid cell killing of infected
target cells was observed, demonstrating the possibility of
generating genetically redirected coronaviruses [103].
The expression cassette was subsequently extended by
inserting the sequence encoding the EGF peptide between
that of the soluble receptor and the His-tag [90]. Again, the
generated recombinant MHVsoR-EGF-His thereby acquired
the ability to cause multiround infection of other-wise non-
susceptible, EGFR-expressing cell cultures in vitro,w i t h
subsequent eﬃcient cytolytic activity [90]. More impor-
tantly, the redirected virus demonstrated oncolytic capacity
also in vivo in an orthotopic U87dEGFR xenograft mouse
model. Survival rates of the mice were signiﬁcantly
longer when the tumor-bearing animals were treated with
MHVsoR-EGF-His than after treatment with control virus
MHVsoR-His or with PBS (Figure 4(a)). In none of the
MHVsoR-EGF-His treated mice-recurrent tumor load could
be detected, demonstrating the strong oncolytic capacity
of such viruses in vivo [90]( Figure 4(b)). Despite the
impressive oncolytic eﬀect in vivo of the redirected MHV,
replication of MHV in non-tumor tissue of the natural host
was observed (Figure 4(c)), presumably because the natural
tropism of MHV was not ablated.
Further experiments demonstrated that the composition
of the bispeciﬁc protein is of critical importance for the
success of generating recombinant oncolytic coronaviruses.
In particular, viable recombinant coronaviruses expressing
a bispeciﬁc scFv from an additional expression cassette in
the viral genome could not be rescued (Figure 5; Verheije
and Rottier, unpublished data). Subsequent introduction of
a bispeciﬁc gene encoding the soR fused to a scFv against
the EGFR did generate viable viruses; however, such viruses
were genetically highly unstable, loosing the foreign gene
usually already within one passage (Figure 5;V e r h e i j ea n d
Rottier, unpublished data). As successful incorporation of
other, even larger, foreign genes at the same position in the
MHV genome has been reported (including for example the
gene-encoding luciferase [104]), the instability of the scFvs
is likely due to their particular sequence composition rather
than to their size.
In conclusion, oncolytic coronaviruses expressing a solu-
ble receptor that is C-terminally extended with a peptide lig-
and have great potential for oncolytic therapy. By expanding
the targeting repertoire through exchange of peptide ligands,
coronaviruses can probably be redirected towards various
tumor epitopes, provided that the binding and fusion ability
oftheviralproteinsaremaintained.Asmurinecoronaviruses
display great species speciﬁcity in their infection, ablation of
the natural tropism will probably not be required, making
MHV a safe candidate oncolytic agent for use in other
mammals, including humans.
5. Conclusions and Perspectives
Appealing as the idea of oncolytic virotherapy may be, its
realization is still disconcertingly remote. What this overview
emphatically reveals is that the ﬁeld of retargeting of viruses
for therapeutic use is in its early infancy. In fact, for the
majority of the viruses studied, scientists are still struggling
with the most fundamental aspects of changing their cell
tropism. Robust platforms for retargeting have actually not
been established yet for any of the viruses. On the positive
side,thefeasibilityofretargetingwas,atleastinvitro,demon-
strated for an increasing number of viruses in the past years.
Clearly the most attractive goal will be to generate oncolytic
viruses that carry the retargeting information in their
genome. Only then will the viruses be able to sustain their
replication in the tumor tissue, irrespective of the retargeting
principle used, that is, whether through the modiﬁcation of
the viral attachment protein or through expression of an
adapterprotein.However,(pre)clinicaldataontheeﬃcacy—
let alone safety—of such transductionally targeted viruses in
vivo are very limited. With one exception (a transduction-
ally and transcriptionally targeted adenovirus [105]), none
of such genetically modiﬁed, tropism modiﬁed oncolytic
viruses have entered phase I clinical trial. This makes it virtu-
ally impossible to compare the viruses reviewed here. Thus,
many hurdles have yet to be overcome before new oncolytic
viruses will reach the clinic. Below, some of the important
future tasks and challenges for the ﬁeld are summarized.
One major challenge at the base of the idea of oncolytic
virotherapy is the availability of suitable target receptors
on tumor cells. Ideally, such receptors are unique or highly
overexpressedinordertoprovidesuﬃcientspeciﬁcityforthe
infection. Recent developments in the proteomics ﬁeld have
already recognized various proteins that are overexpressed in
tumor cells as compared to normal tissue and many more
will hopefully be identiﬁed. It remains, however, question-
able whether truly unique tumor surface proteins exist. This
stresses the need to increase speciﬁcity of oncolytic viruses in
other ways. This can be achieved, for example, by combining
transductional targeting with either transcriptional targeting
or attenuation of the viral genome, both increasing tumor-
speciﬁc replication. In transcriptional targeting, viral genes
essential for replication are placed under control of a tumor-
speciﬁc promoter—which is particularly feasible for DNA
viruses—or under the control of an IRES element in the
case of RNA viruses. Attenuation of the viral genome might
be achieved by the deletion of viral genes that eliminate
functions dispensable in tumor cells, but not in normal
tissue. The feasibility of combining both transductional and
translational targeting has already been demonstrated for
DNA viruses, including adenovirus, while for RNA viruses
investigations rather focus on the transductional targeting of
attenuated viruses.
The natural tropism of the therapeutic virus is another
aspect which needs to be taken into account with regard
to safety. Ablation of the native tropism might be required
for those viruses naturally infecting humans, to prevent the
infection of normal tissue, but also when the virus has a
preference for binding, for instance, to blood substances orAdvances in Virology 11
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Figure 4: In vivo oncolytic activity of murine coronavirus MHV. Mice with established intracranial U87ΔEGFR tumors were treated with
MHV genetically redirected to the EGFR (MHVsoR-EGF-His), the His-receptor (MHVsoR-his), or with PBS. (a) Survival curves. (b)
Histopathological analysis of brains at day 9 posttreatment and at the day of euthanasia (day > 9). Large neoplasms and cystic structures
are indicated by “N” and “C,” respectively. (c) Immunostaining of brains after treatment with MHVsoR-EGF-His using polyclonal
anti-MHV antibodies (Copyright c  American Society for Microbiology, Journal of Virology, Vol. 83, No. 15, P. 7507-16, 2009, DOI
10.1128/JVI.00495-09).
when it exhibits hepatic tropism, both being a major cause
of loss of infectious virus in vivo. The use of nonhuman
viruses for oncolytic therapy gains interest, as such viruses
are usually nonpathogenic for humans and, in addition,
no preexisting antibodies circulate which might limit their
eﬃcacy. However, when adapting to the new host, these
viruses might also pose a risk, as was reviewed in [106].
In order to achieve eﬀectiveeradicationofalltumorcells,
adesirablecharacteristicofoncolyticvirusesistheirabilityto
cause sustained, multiround infection. This can be achieved12 Advances in Virology
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Figure 5: Introduction of bispeciﬁc adapter cassettes into the
coronaviralgenome. SchematicrepresentationoftheMHVgenome
and of the bispeciﬁc expression cassettes introduced herein. The
plus-strand RNA genome contains, from 5  to 3 ,t h ep o l y m e r a s e
precursor gene (ORF1ab), the accessory genes 2a and 2b/HE, the
S gene, the nonessential genes 4ab and 5a, and the genes encoding
the virion proteins E, M, and N. In the recombinant viruses, the
gene cluster 2a + 2b/HE was replaced with an expression cassette
downstream of the translation regulation sequence for protein 2a.
Recombinant MHV viruses were generated by targeted recombi-
nation [35]. Indicated is whether the particular recombinant virus
could be isolated, as conﬁrmed by RT-PCR on virus RNA. In addi-
tion, the ability of such viruses to infect murine and human cells is
depicted (Verheije and Rottier, unpublished data). Abbreviations of
adapters as speciﬁed in the text: “na”: not applicable.
by viruses genetically redirected through the incorporation
of tumor-binding ligands and those having incorporated a
bispeciﬁc adapter into their viral genome The stability of
such recombinant viruses might, however, be a matter of
concern, in particular when the targeting protein is required
toablatethenaturalhumantropism.Ingeneral,DNAviruses
are considered to be more stable than RNA viruses in which,
in addition, the mutation rate is relatively high.
Irrespective of the origin of the virus, immunity induced
upon (repeated) viral treatment against viral antigens but
also against foreign proteins like the bispeciﬁc adapters
expressedfromtheviralgenomemightlimittheeﬀectiveness
of the therapy. To shield viruses from antibodies, polymers
might be used to coat the virion [107]. Yet, this might
compromise the binding of the virus to tumor cells and
can technically only be performed upon application and not
during lateral spread of the virus. Other ways to increase the
delivery of oncolytic virus to tumor cells, especially when
applied systemically, might be the use of carrier cells, which
have the ability to home to the tumor [108].
Inconclusion,transductionallytargetedvirusesmaypro-
vide a much needed tumor-speciﬁc therapy, but researchers
will have to face, besides the technological challenges, a
delicate balance between safety and eﬀectiveness during
development of such new viruses for clinical use. Yet, despite
all problems and concerns, the importance of the ultimate
goalof winning the ﬁghtagainstcancerwarrants the sacriﬁce
of all the energy and creativity needed for its realization.
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